Panbela Therapeutics (PBLA) Stock Price, News & Analysis

Company Overview

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Key Stats

• Today's Range: $0.25 to $0.30
• 50-Day Range: $0.23 to $0.41
• 52-Week Range: $0.23 to $0.48
• Volume: 22,458 shs
• Average Volume: 19,185 shs
• Market Capitalization: $1.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

PBLA Stock Analysis - Frequently Asked Questions

How have PBLA shares performed this year?

Panbela Therapeutics' stock was trading at $0.38 at the beginning of 2025. Since then, PBLA shares have decreased by 34.2% and is now trading at $0.25.
View the best growth stocks for 2025 here.

How were Panbela Therapeutics' earnings last quarter?

Panbela Therapeutics, Inc. (NASDAQ:PBLA) issued its quarterly earnings results on Thursday, August, 10th. The company reported ($159.00) earnings per share for the quarter, missing the consensus estimate of ($94.20) by $64.80.

When did Panbela Therapeutics' stock split?

Panbela Therapeutics shares reverse split on Thursday, January 18th 2024. The 1-20 reverse split was announced on Thursday, January 18th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Panbela Therapeutics?

Shares of PBLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Panbela Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Panbela Therapeutics investors own include Tesla (TSLA), Recursion Pharmaceuticals (RXRX), Aridis Pharmaceuticals (ARDS), Pacific Biosciences of California (PACB), Ginkgo Bioworks (DNA), Tilray (TLRY) and Agnico Eagle Mines (AEM).

Company Calendar

• Last Earnings: 8/10/2023
• Today: 5/16/2025
• Next Earnings (Estimated): 5/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PBLA
• CIK: 1029125
• Web: www.panbela.com
• Phone: (952) 479-1196
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($71.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-25,260,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -302.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.26
• Quick Ratio: 0.26

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($18.37) per share
• Price / Book: -0.01

Miscellaneous

• Outstanding Shares: 4,855,000
• Free Float: 4,855,000
• Market Cap: $1.31 million
• Optionable: Not Optionable
• Beta: 1.34